Literature DB >> 28594311

A lentiviral vector bearing a reverse intron demonstrates superior expression of both proteins and microRNAs.

Brigid Chiyoko Poling1, Kevin Tsai1, Dong Kang1, Linda Ren1, Edward M Kennedy1, Bryan R Cullen1.   

Abstract

While lentiviral expression vectors are widely used in many facets of molecular biology, due to their ability to stably express heterologous genes in both dividing and non-dividing cells, they suffer from the disadvantage that introns inserted into the vector genome are generally rapidly lost by splicing in packaging cell lines. The presence of an intron, if achievable, has the potential to facilitate the expression of transgene cDNAs, as splicing has been extensively shown to facilitate mRNA biogenesis and function. Moreover, if a stable intron could be introduced into a lentiviral vector, this could greatly facilitate the expression of microRNAs (miRNAs), and especially miRNA clusters, as the introduction of pri-miRNA stems into the exonic region of a lentiviral vector can strongly reduce both vector titer and the expression of any miRNA-linked indicator gene due to cleavage of the vector RNA genome by cellular Drosha. Here, we describe a novel lentiviral vector design in which transgenes and/or miRNAs are expressed using an antisense-orientated, inducible promoter driving an expression cassette bearing a functional intron. We demonstrate that this lentiviral vector, called pTREX, is able to express higher levels of both transgenes and pri-miRNA clusters when compared with a closely similar conventional lentiviral vector.

Entities:  

Keywords:  Intron; PKR; Tet-inducible; lentiviral vector; microRNA; transgene expression

Mesh:

Substances:

Year:  2017        PMID: 28594311      PMCID: PMC5785219          DOI: 10.1080/15476286.2017.1334755

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  31 in total

1.  Simian virus 40 late transcripts lacking excisable intervening sequences are defective in both stability in the nucleus and transport to the cytoplasm.

Authors:  W S Ryu; J E Mertz
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

Review 2.  Transcription and processing of human microRNA precursors.

Authors:  Bryan R Cullen
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

3.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Authors:  Frank Stegmeier; Guang Hu; Richard J Rickles; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

4.  A facile method to increase titers of miRNA-encoding retroviruses by inhibition of the RNaseIII enzyme Drosha.

Authors:  Andreas Brandl; Jürgen Wittmann; Hans-Martin Jäck
Journal:  Eur J Immunol       Date:  2010-12-29       Impact factor: 5.532

5.  Production of functional small interfering RNAs by an amino-terminal deletion mutant of human Dicer.

Authors:  Edward M Kennedy; Adam W Whisnant; Anand V R Kornepati; Joy B Marshall; Hal P Bogerd; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  A quantitative analysis of intron effects on mammalian gene expression.

Authors:  Ajit Nott; Shlomo H Meislin; Melissa J Moore
Journal:  RNA       Date:  2003-05       Impact factor: 4.942

7.  Analysis of the stimulatory effect of splicing on mRNA production and utilization in mammalian cells.

Authors:  Shihua Lu; Bryan R Cullen
Journal:  RNA       Date:  2003-05       Impact factor: 4.942

8.  Design of expression vectors for RNA interference based on miRNAs and RNA splicing.

Authors:  Guangwei Du; Joshua Yonekubo; Yue Zeng; Mary Osisami; Michael A Frohman
Journal:  FEBS J       Date:  2006-10-31       Impact factor: 5.542

9.  Nucleic Acid Immunity.

Authors:  G Hartmann
Journal:  Adv Immunol       Date:  2016-12-15       Impact factor: 3.543

10.  Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed.

Authors:  Xuezhong Cai; Alexandra Schäfer; Shihua Lu; John P Bilello; Ronald C Desrosiers; Rachel Edwards; Nancy Raab-Traub; Bryan R Cullen
Journal:  PLoS Pathog       Date:  2006-03-24       Impact factor: 6.823

View more
  6 in total

1.  The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis.

Authors:  Brigid Chiyoko Poling; Alexander M Price; Micah A Luftig; Bryan R Cullen
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

2.  Hnrnpab regulates neural cell motility through transcription of Eps8.

Authors:  Alexa A Lampasona; Kevin Czaplinski
Journal:  RNA       Date:  2018-10-12       Impact factor: 4.942

3.  Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function.

Authors:  Ishak D Irwan; Heather L Karnowski; Hal P Bogerd; Kevin Tsai; Bryan R Cullen
Journal:  mBio       Date:  2020-06-02       Impact factor: 7.867

4.  Detargeting Lentiviral-Mediated CFTR Expression in Airway Basal Cells Using miR-106b.

Authors:  Soon H Choi; Rosie E Reeves; Guillermo S Romano Ibarra; Thomas J Lynch; Weam S Shahin; Zehua Feng; Grace N Gasser; Michael C Winter; T Idil Apak Evans; Xiaoming Liu; Meihui Luo; Yulong Zhang; David A Stoltz; Eric J Devor; Ziying Yan; John F Engelhardt
Journal:  Genes (Basel)       Date:  2020-10-06       Impact factor: 4.141

5.  MicroRNA-23b-3p promotes pancreatic cancer cell tumorigenesis and metastasis via the JAK/PI3K and Akt/NF-κB signaling pathways.

Authors:  Yunan Zhang; Dayang Chen; Guoqiang Zhang; Xiongbo Wu; Liangyun Zhou; Yexin Lin; Junli Ding; Fangmei An; Qiang Zhan
Journal:  Oncol Lett       Date:  2020-08-26       Impact factor: 2.967

6.  β-Globin Lentiviral Vectors Have Reduced Titers due to Incomplete Vector RNA Genomes and Lowered Virion Production.

Authors:  Jiaying Han; Kevin Tam; Feiyang Ma; Curtis Tam; Bamidele Aleshe; Xiaoyan Wang; Jason P Quintos; Marco Morselli; Matteo Pellegrini; Roger P Hollis; Donald B Kohn
Journal:  Stem Cell Reports       Date:  2020-11-12       Impact factor: 7.294

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.